Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. David Bates

General Internal Medicine · BWH

View

Dr. Kartik Goswami

General Internal Medicine · KFH - Santa Clara

View

Dr. Yilin (Gloria) Song

General Internal Medicine · Maryland General Hospital

View

Dr. Rachel Alexander

General Internal Medicine · Georgetown University

View

Dr. Irina Kryzhanovskaya

General Internal Medicine · UCSF

View

Dr. Mathew Alexander

General Internal Medicine · Johns Hopkins

View

Dr. Paul Wurtz

General Internal Medicine · USU

View

Dr. Rabih Geha

General Internal Medicine · UCSF

View

Dr. Paul Williams

General Internal Medicine · Penn State Hershey Medical Center

View

Dr. Natasha Steele

General Internal Medicine · Stanford

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Association Between Baseline Hypertension and Longitudinal Functional Status in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten.

    Feb 1, 2026DOI: 10.1016/j.cardfail.2025.12.010Journal ArticleJCF

    Written by: Nosheen RezaNadim MahmudMelissa A AustinEllen BoakyeEstherland DuqueneyParth PatelAlejandro DE FeriaNicole HornsbyAmy MarzolfAnjali Tiku Owens

    Find these authors on Roon

    ED
    Dr. Estherland Duqueney
    General Internal Medicine · HUP

    Summary

    Hypertension is common in hypertrophic cardiomyopathy (HCM) yet its impact on patients on long-term mavacamten is unknown. In this single-center observational study of 163 patients with symptomatic obstructive HCM treated with mavacamten for up to 108 weeks, hemodynamic and functional responses stratified by baseline hypertension status (60.7% hypertensive) were compared. Mavacamten produced similar reductions in resting and Valsalva LVOT gradients regardless of hypertension status. However, patients with hypertension had a significantly lower probability of achieving NYHA Class I functional status over time (interaction p=0.01). These findings suggest that hypertension-related factors beyond LVOT obstruction may limit complete functional recovery in obstructive HCM despite effective gradient reduction with mavacamten.
    EDDr. Estherland Duqueney

    Dr. Estherland Duqueney

    Internal Medicine · General Internal Medicine
    Hospital of the University of Pennsylvania
    estherland